# US 2003/0229057 A1 · Continuous sulfatase inhibiting progestogen hormone replacement therapy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0229057 A1
- Document ID: US20030229057A1
- Status: Published application
- Kind: A1
- Application number: 10/385,594
- Filed: 2003-03-11
- Published: 2003-12-11
- Earliest claimed: 2002-03-11
- Inventors: Patrick Michel Caubel; Andrew Joseph Friedman
- Web page: https://patentgrep.com/patent/US20030229057A1

## CPC

- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 9/0036: {Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms}
- A61K 9/7023: {Transdermal patches and similar drug-containing composite devices, e.g. cataplasms (galenical aspects of iontophoretic devices A61K9/0009; microneedle arrays A61K9/0021; buccal patches A61K9/006)}
- A61K 31/565: not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K 31/567: substituted in position 17 alpha, e.g. mestranol, norethandrolone
- A61K 31/57: substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61P 15/08: for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A61P 15/12: for climacteric disorders
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A method of hormone replacement therapy is disclosed comprising the step of administering continuously to a post-menopausal or estrogen deficient female in need of such therapy a combination of estrogen in an effective hormone replacement amount and a progestogen which is a potent sulfatase inhibiting progestogen in an amount which is both an effective endometrium protective amount and an effective breast protective amount.

## Claims

### Claim 1

A method of hormone replacement therapy comprising the step of administering continuously to a post-menopausal or estrogen deficient female in need of such therapy a combination of estrogen in an effective hormone replacement amount and a progestogen which is a potent sulfatase inhibiting progestogen in an amount which is both an effective endometrium protective amount and an effective breast protective amount.

### Claim 2

A continuous hormone replacement therapy unit for administration to a post-menopausal or estrogen deficient female in need of such therapy comprising a cycle of separate dosage units adapted for successive daily oral administration for the length of the cycle, wherein said dosage units contain, in admixture with a pharmaceutically acceptable carrier, a combination of an estrogen in an effective hormone replacement amount and a progestogen which is a potent sulfatase inhibiting progestogen in an amount which is both an effective endometrium protective amount and an effective breast protective amount.

### Claim 3

A continuous hormone replacement therapy unit for administration to a post-menopausal or estrogen deficient female in need of such therapy comprising one or more transdermal patches adapted for successive administration for the length of the cycle, wherein said transdermal patches of said unit collectively contain for a cycle of continuous administration a combination of an estrogen in an effective hormone replacement amount and a progestogen which is a potent sulfatase inhibiting progestogen in an amount which is both an effective endometrium protective amount and an effective breast protective amount.

### Claim 4

A continuous hormone replacement therapy unit for administration to a post-menopausal or estrogen deficient female in need of such therapy comprising one or more vaginal rings adapted for successive administration for the length of the cycle, wherein said vaginal rings of said unit collectively contain for a cycle of continuous administration a combination of an estrogen in an effective hormone replacement amount and a progestogen which is a potent sulfatase inhibiting progestogen in an amount which is both an effective endometrium protective amount and an effective breast protective amount.

### Claim 5

A continuous hormone replacement therapy unit for administration to a post-menopausal or estrogen deficient female in need of such therapy comprising a cycle of separate dosage units adapted for successive daily oral administration for the length of the cycle, wherein said dosage units contain, in admixture with a pharmaceutically acceptable carrier, a progestogen which is a potent sulfatase inhibiting progestogen in an amount which is both an effective endometrium protective amount and an effective breast protective amount when used in combination with an effective hormone replacement amount of an estrogen.
